Jiangsu Recbio Technology's (HKG:2179) Chairman Liu Yong resigned to dedicate more time to other commitments, a Tuesday Hong Kong bourse filing said.
Liu will continue to serve as the vaccine maker's general manager.
The firm, on Tuesday, named Xu Haoyu as its new chairman.
Xu has been the chairman and president of Yangtze River Pharmaceutical (Group) since July 2021.